Podcast - Challenges and Innovations in Biliary Tract Cancer (BTC): A Multidisciplinary Task Force Perspective
Podcast
0.5 AMA PRA Category 1 Credit™ ...Faculty
OVERVIEW
Podcast - Challenges and Innovations in Biliary Tract Cancer (BTC): A Multidisciplinary Task Force Perspective is organized by i3 Health.
Statement of Need:
Biliary tract cancer (BTC) encompasses a diverse group of invasive cancers that include gallbladder cancer and intrahepatic, perihilar, and distal cholangiocarcinomas, accounting for less than 1% of all cancers. Each subtype has distinct clinical and molecular features which complicate diagnosis and require personalized workup and assessment for complications (Vogel et al, 2023). Genomic research in recent years has begun to uncover the molecular underpinnings of BTC and introduce the development of targeted therapies for unique molecular alterations (Lee & Song, 2024). With a rapidly evolving diagnostic and therapeutic landscape, it is crucial that the interprofessional team remain up-to-date on emerging treatment strategies in order to provide optimal care for their patients. This podcast will explore challenges and innovations in BTC. It features perspectives from the Multidisciplinary Task Force co-chairs: Anjana Pillai, MD, Professor of Medicine and Surgery and Medical Director of the Liver Tumor Program at the University of Chicago Medicine Comprehensive Cancer Center; and Rachna Shroff, MD, MS, FASCO, Chief of the Division of Hematology/Oncology and Professor in the College of Medicine at the University of Arizona Cancer Center.
Learning Objectives:
Upon completion of this activity, participants should be able to:
- Recognize signs and symptoms of biliary tract cancer (BTC) to help facilitate early diagnosis and intervention
- Explain how molecular testing results inform treatment decisions for patients with BTC
- Discuss the factors involved in selecting initial and subsequent therapies for patients with advanced BTC, incorporating the principles of personalized medicine
- Evaluate the potential of targeting the MDM2-p53 pathway as a treatment approach for advanced BTC
ACCREDITATION & CREDITS
Jointly Accredited Provider:
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians:
i3 Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants/Associates:
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 6/16/2026. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners:
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development:
A maximum of 0.5 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.5 ANCC contact hours of pharmacology credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 0.5 ANCC contact hours.
TARGET AUDIENCE
PhysicianNursingPhysician AssistantSurgical OncologistsPathologistsNurse PractitionersMedical Oncologists Other Healthcare ProfessionalsSPECIALITIES
Oncology
Quick Links